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Generation of c-MyceRtAM-
transduced human late-adherent 
olfactory mucosa cells for potential 
regenerative applications
Gerardo Santiago-toledo1, Melanie Georgiou1, Joana dos Reis1, Victoria H. Roberton  1, 
Ana Valinhas1, Rachael c. Wood1,2, James B. phillips  3,4, chris Mason1,5, Daqing Li6, Ying Li6, 
John D. Sinden4,8, David choi4,6, parmjit S. Jat7 & ivan B. Wall1,2,9
Human olfactory mucosa cells (hoMcs) have been transplanted to the damaged spinal cord both 
pre-clinically and clinically. to date mainly autologous cells have been tested. However, inter-patient 
variability in cell recovery and quality, and the fact that the neuroprotective olfactory ensheathing 
cell (OEC) subset is difficult to isolate, means an allogeneic hOMC therapy would be an attractive “off-
the-shelf” alternative. the aim of this study was to generate a candidate cell line from late-adherent 
hoMcs, thought to contain the oec subset. primary late-adherent hoMcs were transduced with a 
c-MyceRtAM gene that enables cell proliferation in the presence of 4-hydroxytamoxifen (4-OHT). Two 
c-MyceRtAM-derived polyclonal populations, PA5 and PA7, were generated and expanded. PA5 cells 
had a normal human karyotype (46, XY) and exhibited faster growth kinetics than PA7, and were 
therefore selected for further characterisation. PA5 hOMCs express glial markers (p75ntR, S100ß, GFAP 
and oligodendrocyte marker O4), neuronal markers (nestin and ß-III-tubulin) and fibroblast-associated 
markers (CD90/Thy1 and fibronectin). Co-culture of PA5 cells with a neuronal cell line (NG108-15) and 
with primary dorsal root ganglion (DRG) neurons resulted in significant neurite outgrowth after 5 days. 
therefore, c-MyceRtAM-derived PA5 hOMCs have potential as a regenerative therapy for neural cells.
Spinal cord injury (SCI) is a devastating condition affecting 250,000 to 500,000 people a year worldwide1. The 
spinal cord is part of the central nervous system (CNS), a tissue with limited regenerative capacity due to the 
complexity of an unfavourable microenvironment for the re-establishment of neuronal connections2–5. In con-
trast with the peripheral nervous system (PNS), the CNS regenerates slowly due to the formation of “glial scars” 
that are thought to be biochemical and mechanical barriers for axonal regrowth6–9. In the 1980s, studies focused 
on the ability of olfactory neurons to regenerate and form connections after surgical lesions throughout life7,10–12. 
Such unique regenerative properties have been attributed to the anatomical boundaries of the olfactory sys-
tem between the PNS and CNS, as well as the presence of cell types such as neural stem cells (NSCs), olfactory 
ensheathing cells (OECs), and mesenchymal stem cells (MSCs)13–15.
The olfactory mucosa is an accessible source of cells for transplantation as biopsies can be safely taken without 
invasive intracranial surgery unlike the olfactory bulb16,17. Moreover, human olfactory mucosa cells (hOMCs) 
have been successfully transplanted in clinical trials18–21. This work has shown few adverse effects from immu-
nological and microbiological perspectives and autologous hOMC transplantation is generally considered safe22. 
However, an autologous process is difficult to standardise due to large variability in cell composition, thus justi-
fying the need to assess an allogeneic or universal “off-the-shelf ” approach. Allogeneic cell therapy aligns with 
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the concept of cells as pills23, but cells as a product themselves raises challenges for design and standardisation 
of biomanufacturing processes24. According to European Commission guidelines, the sequential generation of 
master cell banks (MCBs) and working cell banks (WCBs) is suggested for the manufacture of advanced therapy 
medicinal products (ATMPs)25. Nonetheless, this cell-banking expansion model assumes that the cell line is stable 
and grows indefinitely to achieve a million-fold expansion of the initial stock26. Human olfactory mucosa cells 
have limited lifespans, an issue that compromises the development of a cell-banking model based manufacturing 
process27. Conditional immortalisation technologies aim to overcome this via controllable or inducible genes 
that, when transduced into cells and under permissive conditions, promote cell proliferation in an immortal state. 
Under non-permissive conditions, cells lose their immortality and return to a “normal” phenotype28. Such an 
approach has been successfully applied to generate neural stem cell lines from human fetal cortical neuroepithe-
lial cells following retroviral transduction with c-MycERTAM gene29. This type of technology consists of a fusion 
gene encoding a chimeric protein composed of the transcription factor c-Myc and the hormone-binding domain 
of a mutant murine estrogen receptor (G525R). The gene product of this fusion no longer binds to 17b -estradiol 
or estrogen-like molecules present in cell culture media, but is responsive to activation by the presence of the 
synthetic drug 4-hydroxytamoxifen (4-OHT)30,31. The expression of the c-MycERTAM protein has been shown to 
be safe and does not affect the phenotype or the potency of transduced cells26,32–34.
In the current work, we present the generation and characterisation of two c-MycERTAM-derived hOMCs pop-
ulations for potential therapeutic application in SCI. First, two independent mucosal biopsies, named as PA5 and 
PA7, were obtained following informed consent under approval from the ethics committee. To enrich neuropro-
tective cell types such as OECs, late-adherent primary hOMCs were retrieved by first removing rapidly adherent 
cells (i.e. fibroblasts) with a 24-hour differential adhesion step. Cells remaining in the supernatant were then 
re-plated and expanded for 12 days to be transduced by retroviral infection. Stably transduced cells were selected 
with geneticin (G418), and incorporation of the c-MycERTAM transgene was further validated at DNA and protein 
level. Karyotype analysis and growth kinetics characterisation was performed for both populations. Due to their 
karyotypic stability and faster growth kinetics, PA5 hOMCs were chosen for further phenotypic characterisa-
tion. Biomarker expression of PA5 hOMCs was assessed by immunocytochemistry to confirm the presence of 
characteristic glial (p75NTR, S100 calcium-binding protein B (S100ß), glial fibrillary acidic protein (GFAP), and 
oligodendrocyte marker O4), neuronal (ß-III-tubulin and nestin), and fibroblast-associated (Thy1 and fibronec-
tin) markers reported in primary hOMCs16,35–37. To mimic a cell contact regeneration process, co-cultures of PA5 
hOMC monolayers were performed with the NG108-15 cell line, a hybrid rat glioma mouse neuroblastoma cell 
line, and with primary dorsal root ganglion (DRG) neurons. In these systems, PA5 hOMCs were able to enhance 
neurite outgrowth. Clones from polyclonal populations such as PA5 c-MycERTAM-derived hOMCs could be fur-
ther derived, expanded, banked, and screened to generate an allogeneic cell therapy product for the treatment of 
spinal cord injury.
Results
Validation of c-MyceRtAM transduction. After selection of stably transduced late-adherent hOMCs with 
geneticin (G418), successful incorporation of c-MycERTAM to PA5 hOMCs was confirmed at both DNA and 
protein levels. Genomic insertion of the oncogene was evaluated by amplification of genomic DNA (gDNA) by a 
standard end-point PCR protocol. Specific primers targeted to the junction of c-Myc and ERTAM were designed to 
amplify a region of 265 bp. Amplification of endogenous c-Myc was performed to verify amplification of gDNA 
samples (Fig. 1). Sequences and migration profiles of PCR products of PA5 cells were compared to those of 
CTX0E03 cells (ReNeuron Ltd.) as a positive control, and primary human olfactory mucosa cells (phOMCs) as a 
negative control. PCR products were fractionated by agarose electrophoresis, purified and sequenced by Eurofins 
Genomics. Bands of identical sizes were obtained for both c-Myc and c-MycERTAM targets when amplified using 
c-Myc specific primers (Fig. 1A lanes 1–3). When amplification was carried out with primers across the junction 
between c-Myc and ERTAM, identical sized bands were obtained for PA5 hOMCs and CTX030E (Fig. 1A lanes 4 
and 6), whereas no product was obtained for primary hOMCs (Fig. 1A lane 5). Moreover, sequence alignment 
yielded 96% to 99% homology between PA5 hOMCs and CTX0E03 c-MycERTAM junction sequences. Western 
blotting of PA5 and PA7 hOMCs and CTX0E03 lysates revealed that they expressed the c-MycERTAM protein 
product, in contrast to phOMCs (Fig. 1B,C). The signal from both PA5 and PA7 gene products were of the same 
size as the CTX0E03 protein with an apparent molecular weight of 90 kDa, distinguishable from endogenous 
c-Myc (Fig. 1B, band at 55 kDa) and ERα (Fig. 1C, band at 60 kDa). The expression of c-MycERTAM protein for 
PA5 and PA7 hOMCs was at a lower level relative to CTX0E03 cells. Nonetheless, these results were consistent 
with gDNA amplification. These analyses confirmed that PA5 cells successfully incorporated the c-MycERTAM 
fusion gene into their genome, and both PA5 and PA7 hOMCs expressed its respective product at the protein 
level.
Karyotype. Incorporation of immortalisation genes has raised concerns about potential karyotypic instability 
associated with tumori-genesis38,39. Moreover, karyotypic abnormalities have been reported in studies of condi-
tional immortalisation of human OB-OECs40,41. To determine if chromosomic instability would arise after trans-
duction, standard Giemsa banding (G-banding) karyotypic analysis was carried out for c-MycERTAM-derived 
hOMCs. A representative cell karyotype is shown in Fig. 1D.
PA5 hOMCs at passage 14 (PDL 16.6) displayed a normal diploid male karyotype (46, XY) with no visible 
chromosomic aberrations, i.e. absence of polyploidy, pseudodiploidy, and hypodiploidy. When the same analysis 
was performed for PA7 hOMCs at passage 12 (PDL = 16.79); however, these showed a mosaic karyotype as 3 of 
20 cells were hypodiploid (45, X) (Fig. 1E).
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Growth kinetics. Once the stable incorporation of c-MycERTAM was confirmed, cell growth was monitored 
manually by performing standard hemocytometer cell counting at every passage for 60 days (Fig. 2A) from pas-
sage 4 to 18 for PA5 hOMCs and from passage 9 to 25 for PA7 hOMCs. PA5 hOMCs showed faster growth kinet-
ics than PA7 hOMCs. By day 60, a total of 31.67 cumulative population doublings were observed for PA5 hOMCs, 
in contrast with 10.34 doublings for PA7 hOMCs. PA5 hOMCs at day 6 were growing at a rate of 1.61 day−1 and 
decreased down to 0.17 day−1 at day 60, whereas PA7 hOMCs rates followed a similar pattern from 0.14 day−1 at 
day 6 down to 0.07 day−1 at day 60. Thus, doubling times for PA5 hOMCs increased from 0.43 days to 4.05 days, 
and from 4.88 days to 9.91 days for PA7 hOMCs in the same period. Phase contrast images revealed that PA5 
hOMCs at passage 9 had a small, elongated morphology, whereas PA7 hOMCs at passage 10 were larger with 
higher cytoplasm-to-nucleus ratio (Fig. 2B), a characteristic morphology of senescent cells. After these observa-
tions in cell growth, PA5 hOMCs were chosen for further phenotypic characterisation.
Biomarker expresion of PA5 c-MycERtAM-derived hoMcs. Initial characterisation of biomarker 
expression was assessed by immunocytochemistry (ICC) to verify whether PA5 c-MycERTAM-derived hOMCs 
express biomarkers previously reported for cell types present in the olfactory mucosa such as olfactory ensheath-
ing cells (OECs)16,18,20,42,43 and mesenchymal stromal cells (MSCs)15,36,37,44,45. PA5 hOMCs at passage 8 and phO-
MCs at passage 3 were stained for OEC markers (p75NTR, S100ß, GFAP and oligodendrocyte marker O4), neural 
markers (nestin and ß-III-tubulin) and fibroblast associated markers (fibronectin, CD90/Thy1) (Fig. 3). Both 
Figure 1. c-MycERTAM transduction characterisation and karyotyping of human olfactory mucosa cells. (A) 
The incorporation of the c-MycERTAM construct in PA5 cells was analyzed by genomic DNA amplification 
(gDNA) using specific primers (lanes 4–6). CTX0E03 cells were used as a positive control and primary cells 
from the olfactory mucosa (phOMCs) as a negative control. Amplification of endogenous c-Myc was performed 
to verify amplification of gDNA samples (lanes 1–3). Finally, gDNA and primers were fractionated to verify 
integrity (lanes 7–12). Expression of the c-MycERTAM protein is shown by western blotting using (B) anti-c-
Myc and (C) anti-ERα primary antibodies. CTX0E03 cells were used as a positive control and primary cells 
(phOMCs) as a negative control. (D) PA5 cells had a normal 46, XY karyotype, whereas (E) PA7 cells had a 
mosaic karyotype with hypodiploidy (45, X) in 3 of 20 cells.
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hOMC populations were positive for tested markers, with the exception of GFAP in phOMCs. Also, a weaker 
signal for CD90/Thy1 was observed on PA5 hOMCs in comparison with phOMCs. It must be noted that although 
OM biopsies show intrinsic variability in terms of cell composition46, both PA5 hOMCs and phOMCs obtained 
from different patients, showed similar biomarker profiles. Therefore, this characterisation confirmed that PA5 
hOMCs are positive for biomarkers that have been reported in cells isolated from the human olfactory mucosa.
Figure 2. (A) Growth of PA5 and PA7 c-MycERTAM-derived human olfactory mucosa cells was followed for 60 
days. (B) Morphology of PA5 and PA7 cells at 100 × total magnification. Scale bar represents 400 µm.
Figure 3. Biomarker expression was assessed by immunocytochemistry for PA5 c-MycERTAM-derived hOMCs 
at passage 8, and primary cells (phOMCs) at passage 3. Both cell populations stained positive for OEC markers 
(p75NTR, S100ß and oligodendrocyte marker O4), neural markers (nestin and ß-III-tubulin), and fibroblast-
associated markers (fibronectin, CD90/Thy1) for PA5 and primary hOMCs. Primary hOMCs were negative for 
GFAP, whereas PA5 hOMCs were positive for this glial marker. Scale bars represent 200 µm.
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Co-culture with NG108-15 cells. To quantify the potency of PA5 hOMCs, cells were assessed at passage 
8 and passage 15 for their ability to support neurite outgrowth. This was assessed using a co-culture assay with 
hybrid NG108-15 cells. This co-culture assay has been used to investigate the ability of various candidate cell ther-
apies to stimulate NG108-15 cell neurite outgrowth in comparison with a positive control, e.g. Schwann cells47–50. 
Mean neurite length, mean longest neurite, and mean number of neurites per neuron measurements were per-
formed in NeuronJ51 by manual tracing of ß-III-tubulin positive neurites in fluorescent images which were clearly 
distinguishable with immunostaining and morphology from hOMCs (Fig. 4E). Overall, PA5 hOMCs were able 
to co-exist in vitro with NG108-15 cells. The mean neurite length was significantly (H(3, 8) = 9.667, p = 0.0279) 
higher for NG108-15 cells co-cultured in the presence of PA5 hOMCs in passage 18 (34.01 ± 6.85 µm) when 
compared to the NG108-15 negative control (17.75 ± 0.75 µm) (Fig. 4B). Among these sprouts, the mean longest 
neurite was significantly (F(3, 8) = 10.48, p = 0.0038) longer for NG108-15 cells co-cultured with PA5 hOMCs 
in passage 8 (65.60 ± 3.83 µm), with PA5 hOMCs in passage 18 (82.06 ± 25.24 µm), and with the F7 Schwann cell 
positive control (44.77 ± 1.99 µm) (Fig. 4C). When calculating the mean ratios of neurites per neuron, they were 
Figure 4. Co-culture of PA5 hOMCs at passage 8 (PDL 10) and passage 15 (PDL 18) with NG108–15 cells. (A) 
Timeline of the co-cultures with NG108-15 cells. (B) Mean neurite length, (C) mean longest neurite, and (D) 
mean number of neurites per neuron measurements were performed manually. (E) Representative images of co-
cultures stained with ß-III-tubulin at 100 × total magnification and zoomed regions with NG108-15 cells. Scale 
bar represents 400 µm at 100 × total magnification, and 200 µm at the zoomed regions. Data are mean SEM, 
n = 3.
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significantly (F(3, 8) = 11.55, p = 0.0028) higher for NG108-15 cells co-cultured with PA5 hOMCs in passage 8 
(0.37 ± 0.06), PA5 hOMCs in passage 18 (0.42 ± 0.07), and the F7 Schwann cell positive control (0.30 ± 0.09) 
(Fig. 4D). In summary, PA5 hOMCs showed regenerative potential by promoting NG108-15 neurite outgrowth 
and performed comparably or better than the F7 Schwann cell positive control.
co-culture with dorsal root ganglion (DRG) neurons. After co-culturing PA5 hOMCs in a cell con-
tact model with NG108-15 cells, PA5 hOMC monolayers were also evaluated using primary rat dorsal root 
ganglion (DRG) neurons. These were counterstained with specific antibodies targeted to S100ß (green) and 
Figure 5. Co-culture of PA5 hOMCs with DRG neurons. (A) Timeline of the co-cultures with DRG 
neurons. (B) Mean neurite length, (C) mean longest neurite, and (D) mean number of neurites per neuron 
measurements were performed manually. Representative images of co-culture stained with ß-III-tubulin (red) 
and S100ß (green) at 100 × total magnification and zoomed regions with DRG neurons. Scale bar represents 
400 µm at 100 × total magnification, and 200 µm at the zoomed regions. Data are mean SEM, n = 3.
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ß-III-tubulin after 3 and 5 days of co-culture (Fig. 5). DRG cells co-cultured with F7 Schwann cells had signifi-
cantly (F(2,12) = 41.06, p < 0.0001) higher mean neurite length (116.60 ± 45.40 µm) than those grown with PA5 
hOMCs (72.60 ± 29.7 µm) or with no cells (50.2 ± 18.2 µm) at day 3. However, no differences within PA5 hOMCs 
and F7 were observed at day 5 (Fig. 5B). Longest neurites were measured for DRG cells grown in the presence 
of PA5 hOMCs and F7 Schwann cells (Fig. 5C). At both 3 and 5 days of culture, DRG cell co-cultured with F7 
Schwann cells and PA5 hOMCs had significantly (F(2,12) = 59.14, p < 0.0001) longer neurites than those cultured 
alone. At day 3 there was a significant (F(2,12) = 59.14, p = 0.0033) difference of 120 µm between F7 co-culture 
and PA5 hOMCs. However, the difference of mean longest neurites between F7 and PA5 hOMCs was no longer 
significant at day 5, indicating that the PA5 hOMCs were equivalent to the positive control.
A significantly (F(2,12) = 36.88, p < 0.0001) higher number of sprouts per cell were quantified on DRG neu-
rons grown with F7 Schwann cells at day 3 (6.81 ± 3.53) and day 5 (4.57 ± 1.37) (Fig. 5D). Interestingly at day 5, 
DRG cells co-cultured with PA5 hOMCs had the highest number of neurites per cell (5.26 ± 3.38), slightly higher 
than those grown with F7 Schwann cells (4.57 ± 1.37). These co-culture trends show that PA5 hOMCs also pro-
mote neurite outgrowth from rat DRGs. This process seems to be slower for DRG neurons co-cultured with PA5 
hOMCs than those grown with F7 cells; however, it provides additional evidence to support the suitability of PA5 
hOMCs for promoting neurite outgrowth in the damaged spinal cord.
Discussion
Although autologous human olfactory mucosa cells (hOMCs) have been successfully transplanted into the dam-
aged spinal cord, as yet no study has achieved successful expansion of this cell population to provide an allogeneic 
source of cells for transplantation. The pressure to generate cell lines as biomedical research tools has triggered 
the development of approaches for the production of stable and well characterised cells. Initially cell lines were 
obtained from tumours or spontaneous variants that grew readily in culture28,52,53. It was not until the develop-
ment of vectors for insertion of desired genes into the genome that the generation of immortalised cells that were 
not derived from tumours became possible. Expression of immortalisation genes raises safety concerns due to 
them conferring an unlimited proliferative potential, which may lead to tumorigenesis54. There are consequently 
a number of challenges to be addressed for conditional immortalisation technologies, most of them safety related 
(e.g. transgene stability, controlability, silencing prior to transplantation). Nonetheless, the success of cases such 
as CTX0E03 by ReNeuron Ltd. has opened R&D opportunities across the cell therapy industry to generate com-
mercially sustainable manufacturing processes28. Conditional immortalisation technologies have the potential to 
produce enough cells for the generation of MCBs and WCBs.
In this study, we successfully incorporated a c-MycERTAM conditional immortalisation gene into the genome 
of two polyclonal populations of hOMCs via retroviral transduction. Late-adherent hOMCs were chosen based 
on the fact that fibroblasts attach to uncoated polystyrene surfaces rapidly55 (<one hour), whereas other cell 
types linked to regeneration (such as olfactory ensheathing cells) do not attach within the first 24–48 hours35,56. 
It is therefore possible to enrich these candidate regenerative cells by selectively removing mucosal fibroblasts 
based on adhesion properties. After selection of stably transduced cells, the incorporation of the transgene was 
verified at DNA and protein levels. Both c-MycERTAM-derived populations incorporated the transgene into their 
genome and expressed the c-MycERTAM gene product. In the first thirty days of culture, a 40-fold expansion in 
PA5 hOMC numbers was achieved, with progressive decrease in growth kinetics. Transduction of genes under 
the cytomegalovirus (CMV) immediate early promoter has been performed to successfully generate CTX0E03 
neural stem cells29. Interestingly, it has been shown that CMV promoters can undergo epigenetic silencing32, 
and can be either strong or weak to express proteins in particular cell types57,58. As the signal of c-MycERTAM 
protein for PA5 hOMCs was weaker when compared to the CTX0E03 control, it might be possible that silencing 
events had been occurring in long-term culture, which remain to be further characterised. Nonetheless, PA5 
hOMCs were further investigated for phenotypic characterisation due to their faster growth kinetics and kary-
otype stability when compared to PA7 hOMCs or to other published reports of conditionally immortalised glia 
from the olfactory bulb40,59,60. PA5 hOMCs expressed glial markers (p75NTR, S100ß, oligodendrocyte marker O4), 
neuronal markers (nestin, ß-III-tubulin), and fibroblast-associated markers (fibronectin, CD90/Thy1) reported 
in cell types isolated from olfactory mucosa such as olfactory ensheathing cells16,18,20,42,43, and more recently, 
mesenchymal stem cells15,36,37,44,45 from the lamina propria. Moreover, a potency assay using a co-culture model 
based on stimulation of axonal growth in NG108-15 hybrid cells revealed that PA5 cells had promising functional 
activity. Previous PNS repair studies using this co-culture model have shown that neurite outgrowth in vitro can 
be consistently associated with Schwann cell potency to enhance neurite length in vivo47,48. The effect of PA5 cells 
on neurite outgrowth was comparable to F7 Schwann cells, assessed using several neurite outgrowth parameters. 
Measurements of mean number of neurites per neuron, mean length and mean longest length were higher over-
all for PA5 hOMCs than for the F7 Schwann cell positive control, demonstrating that PA5 hOMC monolayers 
promoted neurite outgrowth of NG108-15 cells at two separate passages. A similar effect on neurite growth was 
observed when primary rat DRG neurons were used in the co-culture model instead of the NG108-15 cell line. 
This confirmed the ability of PA5 hOMCs to support neuronal cell activity in vitro. These preliminary co-culture 
data are promising, however future studies using in vivo models will be necessary to determine whether cell trans-
plantation into damaged spinal cord can lead to functional recovery. They will also be important to ensure that 
the gene-modified cells have an acceptable safety profile, similar to that seen in earlier c-MycERTAM-transduced 
cells28,29.
In summary, we demonstrate proof-of-principle for increased expansion of hOMCs using c-MycERTAM tech-
nology to produce a population of cells that could be used to expand cells for transplantation, and further sepa-
rated to select clones with desirable regenerative properties. This study provides early evidence that late-adherent, 
c-MycERTAM-derived hOMCs are a promising candidate for supporting neural regeneration. This approach may 
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underpin the development of an off-the-shelf advanced therapy medicinal product for the treatment of CNS 
injuries such as those of the spinal cord.
Methods
primary culture. Adult olfactory mucosa biopsies were taken in accordance to regulatory requirements fol-
lowing informed consent under approval from the NHS Research Ethics Service (REC reference 18/LO/0108, 
IRAS project ID 229297) at the National Hospital for Neurology and Neurosurgery. All methods were per-
formed in accordance with the relevant guidelines. Biopsies were taken and primary culture was performed46. 
After surgery, tissue was transported in DMEM/F12 (Gibco, Life Technologies) + GlutaMAXTM-I (Gibco, Life 
Technologies) + 10% FBS (Sigma) + 1% penicillin/streptomycin (P/S) medium to the laboratory, and allowed to 
rest for 2 hours. The olfactory mucosa (OM) was dissected and chopped using a scalpel (TAAB). Sliced OM was 
rinsed in Hank’s Balanced Salt Solution (HBSS, Gibco, Life Technologies) to remove mucus and conditioned with 
fresh FBS expansion medium. Rinsed OM was then cut into small pieces of approximately 0.5 mm2, transferred 
to 15-mL centrifuge tubes and incubated in 2 mL of dispase II (Boehringer, 2.4 U/mL in FBS expansion medium) 
at 37 °C for 45 minutes. Dissociated cells were centrifuged (400 × g for 5 min, RT), and transferred to a new 
tube with collagenase Type H from Clostridium histolyticum (Sigma, 0.0025 g/mL in FBS expansion medium). 
Primary human olfactory mucosa cells (phOMCs) were incubated at 37 °C for 15 minutes, and mechanically 
triturated every 5 minutes. After enzymatic dissociation, polyclonal populations of phOMCs were plated onto 
Petri dishes, and maintained in standard culture conditions at 37 °C, 5% CO2. A differential adhesion step was 
carried out 24 hours later to remove the rapidly adhering fibroblasts, allowing cell types with low adhesion rates 
(>24 hr) such as OECs to be enriched in the subsequent culture35. Late-adherent hOMCs in the supernatant were 
re-plated onto a new Petri dish pre-coated with poly-L-lysine (PLL, Sigma, 100 µg/mL). Cells were maintained in 
standard culture conditions at 37 °C, 5% CO2, and fed every 48 hours for 12 days prior to transduction with the 
c-MycERTAM retrovirus (Fig. 6).
c-MyceRtAM transduction. Cell populations were generated by viral transduction of primary human olfac-
tory mucosa cells with the c-MycERTAM fusion gene (Fig. 7). Briefly, c-MycERTAM construct cloned into pLNCX-2 
was packaged as an amphotrophic virus using the TEFLY-A packaging cell line29. Virus was harvested in DMEM/
F12 (Gibco, Life Technologies) + GlutaMAXTM-I (Gibco, Life Technologies) + 10% FBS (Sigma) + 1% penicil-
lin/streptomycin (P/S, Sigma) medium over an 8 hour period and filtered through a 0.45 mm filter (Millipore) 
to remove cell debris. Primary human olfactory mucosa cells (hOMCs) were expanded for 12 days after sur-
gery, and exposed to viral supernatants in the presence of polybrene (4 mg/mL) for 8 hours. Subsequently, cells 
were fed with fresh expansion medium, and viral infections were carried out sequentially three times at intervals 
of 16 hours to maximise the efficiency of stable viral transduction. After the infections, cells were exposed to 
geneticin (G418, 150 µg/mL) to select stably transduced cells. Non-infected primary hOMCs were also exposed 
to G418, and when no cells remained in the untreated dish by day 10, G418-resistant hOMCs were banked and 
further characterised. Two c-MycERTAM-derived polyclonal populations, named PA5 and PA7, were used in this 
study.
Figure 6. Structure of the c-MycERTAM provirus.
Figure 7. Generation of c-MycERTAM - derived populations of human olfactory mucosa cells (hOMCs).
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cell culture. PA5 and PA7 hOMCs were grown in complete expansion medium (DMEM/F12 (Gibco, Life 
Technologies) + GlutaMAXTM-I (Gibco, Life Technologies) + 10% FBS (Sigma) + 100 nM 4-OHT (Sigma)). 
When cells reached 60–80% confluency, they were washed with HBSS, and passaged using TryPLETM (Gibco, 
Life Technologies) for 6 min at 37 °C. After incubation, dissociation reagent was stopped by dilution in expansion 
media. The cell suspension was centrifuged (400 × g for 5 min, RT) and cells resuspended in a known volume of 
media. Cells were counted by hemocytometer, plated at a seeding density of 6,000 cells/cm2, and maintained in 
standard culture conditions at 37 °C, 5% CO2, with feeding every 48 hours.
Manual cell counting. Cells were counted using a Bright-Line™ (Reichert, NY, USA) hemocytometer under 
a Life Technologies EVOS® inverted light microscope. 10 mL of cell suspension were applied to each chamber. 
Twelve squares were manually counted and averaged (Eq. 1).
∑= ×
=
n
n
n1 10
(1)
cells mL
sq i
n
i/
1
4
sq
where
nsq: Number of squares; and ni: Number of cells on each square.
Population doubling level (PDL) was calculated (Eq. 2) to estimate the age of the culture based on the total 
number of times cells that have divided, and also taking into account cell yield and seeding number60.
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where
PDLi: Final population doubling level; PDLi−1: Initial population doubling level; xfi: Final cell number; and x0i: 
Initial cell number.
Data were recorded in Microsoft Excel files while passaging and analysed by GraphPad Prism® 7.
Karyotyping. Cells were expanded until 60–80% confluence was reached. Live cells were shipped to Cell 
Guidance Systems Ltd. (Cambridge, UK) for karyotype analysis. Briefly, samples of 20 random cells were picked, 
fixed and stained. Additionally all cells used in this work were routinely tested for mycoplasma every 6 months 
(Surrey Diagnostics, Cranleigh, UK).
pcR. Genomic DNA (gDNA) was extracted using a Blood and Cell Culture mini-kit (QIAGEN). Adherent 
cells were harvested by centrifugation and excess medium was removed prior to storage at −80 °C. gDNA samples 
were eluted in 70% (% v/v) ethanol, centrifuged and finally diluted in 100 µL of TE buffer (Sigma). Samples were 
quantified in ng/mL by measuring 260/280 nm absorbance ratios on a NanoDrop ND-1000 spectrophotome-
ter (Thermo Scientific). 100 ng of gDNA template was mixed with a Q5® High-Fidelity (New England Biolabs) 
Master Mix, DNAse-free water and specific PCR primers (Table 1) for a 25 mL reaction in a T100TM Thermal 
Cycler (Bio-Rad). PCR products were run on 2% agarose gels in TBE buffer (Gibco, Life Technologies) stained 
with 0.5 µg/mL ethidium bromide (Sigma). Bands were imaged in a GelDoc 2000 device (Bio-Rad).
immunocytochemistry (icc). PA5 hOMCs were grown in T-flasks and re-plated onto PLL-coated well 
plates at 6,000 cells/cm2. Cells were washed with PBS and fixed overnight with 4% paraformaldehyde (PFA, 
Sigma) at 4 °C. Subsequently they were permeabilised with 0.1% Triton X-100 (Sigma) for 20 min at RT, and 
blocked with 5% goat serum (Dako) for 30 min at RT. Samples were incubated with primary antibody (1:200, 
Table 2) for 90 minutes at RT, followed by incubation with secondary antibody (1:200, Table 2) and Hoechst 
33342 (1:3000, Invitrogen) for 45 minutes at RT. PBS washes were performed three times for 5 minutes between 
each step. Five pictures per well were taken under an Eclipse TE2000-U microscope (Nikon) at 100 and 200 total 
magnification.
SDS-PAGE/Western blot. Reducing buffer (26% glycerol, 10% ß-mercaptoethanol (BME), 0.34 M Tris 
(pH = 7.3), and 0.1 g/mL sodium dodecyl sulfate) was added to the samples. Reduction was performed at 95 °C for 
10 minutes, and equal amounts of protein were fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) 
with 4–20% gels (Bio-Rad). The proteins were transferred to PVDF membranes, blocked for one hour with 5% 
milk in 0.5 TBS + 0.05% Tween 20 (TBST) buffer, and incubated for 16 hours at 4 °C with primary antibody 
(1:200 in 5% milk in 0.5 TBST, Table 3). After rinsing, the blots were incubated for 2 hours at 4 °C with secondary 
antibody (1:2000 in 5% milk in 0.5 TBST, Table 3) conjugated with HRP. Membranes were rinsed 5 times with 
Target Primer Sequence (5′-3′) Amplicon size Tm (°C)
c-MycERTAM Forward GAAAAGGCCCCCAAGGTAGT 265 bp 65.1
c-MycERTAM Reverse TCTGGTCAGCTGTCAAGGAC 265 bp 63.2
Endogenous c-Myc Forward GGACTTGTTGCGGAAACGAC 581 bp 59.4
Endogenous c-Myc Reverse GGGAGGGGGAAGAAACGAAA 581 bp 59.4
Table 1. Primers for gDNA amplification.
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0.5 TBST between each step. Finally, blots were developed by rinsing for 2 minutes with fresh SuperSignal™ West 
Femto Maximum Sensitivity ECL Substrate (Thermo Scientific) in an Amersham Imager 600 (GE Healthcare).
Co-culture with NG108-15 cells. Co-cultures in the first stage of this study used established cell lines 
rather than primary cells to avoid variability in cell populations. PA5 hOMCs were co-cultured with NG108-15 
cells (ATCC® HB-12317®TM), a hybrid rodent glioma-neuroblastoma cell line61 (Fig. 4A). NG108-15 cells were 
expanded on T-75 flasks (Thermo-Scientific) freshly coated with poly-L-lysine (PLL, Sigma, 100 µg/mL) for two 
passages according to supplier protocols in DMEM/F12 (Gibco, Life Technologies) + GlutaMAXTM-I (Gibco, 
Life Technologies) + 10% FBS (Sigma) medium. The rat SCL 4.1/F7 (ECACC 93031204) Schwann cell line was 
used as a positive control62. Similarly to NG108-15 cells, F7 cells were expanded on T-75 flasks with no coating 
for two passages according to supplier protocols in DMEM/F12 (Gibco, Life Technologies) + GlutaMAXTM-I 
(Gibco, Life Technologies) + 10% FBS (Sigma) medium. To start the co-cultures, PA5 and F7 cells were cul-
tured, and re-plated at 6,000 cells/cm2 onto 24-well plates (Thermo-Scientific) freshly coated with PLL (Sigma, 
100 µg/mL). 4-OHT, which activates the c-MycERTAM conditional immortalisation system, was removed from 
PA5 hOMC media during cell seeding. After 24 hours, NG108-15 cells were detached and plated at a seeding 
density of 500 cells/well onto 24-well plates with monolayers of PA5 or F7 cells, and onto negative control wells 
with NG108-15 cells only. Cells were fed with DMEM/F12 (Gibco, Life Technologies) + GlutaMAXTM-I (Gibco, 
Life Technologies) + 10% FBS (Sigma) every 48 hours, and fixed after 5 days of co-culture. Immunocytochemistry 
was carried out as described previously. A total of 15 frames were taken per condition (5 per technical triplicate) 
at 100 × total magnification in the EVOS® FL Imaging system (Thermo-Scientific). Neurite quantification was 
performed manually in ImageJ using the NeuronJ plugin51. Data were recorded in Microsoft Excel files and ana-
lysed by GraphPad Prism® 7.
isolation of dorsal root ganglion (DRG) neurons. All animal tissue was obtained according to the UK 
Home Office regulations following approval by the UCL Research Ethics Committee. To obtain the dorsal root 
ganglia (DRGs), first the spinal column was excised from adult Sprague-Dawley rats (250–350 g) that were culled 
using carbon dioxide (CO2) asphyxiation. The column was divided in half in the sagittal plane to expose the spi-
nal cord, and the cord tissue was removed to expose the DRGs in the intervertebral foramen. Under a dissecting 
microscope, the DRGs were removed and placed in a petri dish containing growth medium. Twenty DRGs were 
collected from the thoracic and lumbar regions, and cleaned by removal of the roots, capsule and capillaries. The 
cleaned DRGs were dissociated after incubation in 2 mL 0.125% collagenase type IV (prepared in basal medium 
supplemented with 100 mg/mL penicillin/streptomycin solution) at 37 °C, 5% CO2 in air for 90 minutes. The 
collagenase-treated explants were mechanically dissociated (triturated) with a 1 mL pipette. Collagenase was 
removed by two 20 mL spin washes in growth medium at 400 × g for 5 minutes. The pellet was resuspended in 
growth medium supplemented with 0.01 mM cytosine arabinoside (to deplete the dividing satellite glial cells 
and any fibroblasts, leaving an enriched primary culture of adult rat neurons), and plated in a poly-L-Iysine 
(PLL)-coated (50 µg/mL, RT, 30 minutes) T-75 flask (1–2 rats per flask) and incubated at 37 °C, 5% CO2 for 
24 hours before use. They were removed by trypsinisation with 0.25% trypsin/EDTA solution for 10 minutes at 
37 °C, 5% CO2. Cells were recovered by centrifugation at 400 × g for 5 minutes and then resuspended in growth 
medium for co-cultures.
Host Antibody Reactivity Company Code
Rabbit IgG polyclonal p75NTR Millipore ab105389
Rabbit IgG polyclonal S100ß Dako Z0311
Rabbit IgG polyclonal GFAP Dako Z0334
Rabbit IgG monoclonal Nestin Millipore MAB5326
Mouse IgG monoclonal CD90/Thy1 Millipore MAB1406
Mouse IgG monoclonal ß-III-tubulin Sigma T8660
Mouse IgG monoclonal Fibronectin Sigma F6140
Mouse IgG monoclonal O4 Millipore MAB345
Goat IgG DyLight 488 Rabbit IgG (H + L) Thermo Scientific 35552
Goat IgG DyLight 488 Mouse IgG (H + L) Thermo Scientific 35503
Table 2. Primary and secondary antibodies for immunocytochemistry (ICC).
Host Antibody Reactivity Company Code
Mouse IgG monoclonal c-Myc Santa Cruz sc-42
Rabbit IgG polyclonal ER Santa Cruz sc-542
Mouse IgG monoclonal ß-actin Abcam ab8226
Goat IgG-HRP Rabbit IgG (H + L) Abcam ab6721
Goat IgG-HRP Mouse IgG (H + L) Abcam ab6789
Table 3. Primary and secondary antibodies for western blotting (WB).
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co-culture with dorsal root ganglion (DRG) neurons. In the next stage, PA5 hOMCs were co-cultured 
with primary human DRG neurons (Fig. 5A). DRG neurons were expanded on T-75 flasks (Thermo-Scientific) 
freshly coated with poly-L-lysine (PLL, Sigma, 100 µg/mL) for two passages in DMEM/F12 (Gibco, Life 
Technologies) + GlutaMAXTM-I (Gibco, Life Technologies) + 10% FBS (Sigma) medium. To start the co-cultures, 
PA5 and F7 cells were cultured, and re-plated at 6,000 cells/cm2 onto 24-well plates (Thermo-Scientific) 
freshly coated with PLL (Sigma, 100 µg/mL). 4-OHT, which activates the c-MycERTAM conditional immortal-
isation system, was removed from PA5 hOMC media during cell seeding. After 24 hours, DRG neurons were 
detached and plated at a seeding density of 500 cells/well onto 24-well plates with monolayers of PA5 or F7 
cells, and onto negative control wells with DRG neurons only. Cells were fed with DMEM/F12 (Gibco, Life 
Technologies) + GlutaMAXTM-I (Gibco, Life Technologies) + 10% FBS (Sigma) every 48 hours, and fixed after 
3 and 5 days of co-culture. Immunocytochemistry was carried out as described previously. A total of 15 frames 
were taken per condition (5 per technical triplicate) at 100 total magnification in the EVOS® FL Imaging system 
(Thermo-Scientific). Neurite quantification was performed manually in ImageJ using the NeuronJ plugin51. Data 
were recorded in Microsoft Excel files and analysed by GraphPad Prism® 7.
Statistical analysis. Statistical analyses were conducted with one-way ANOVA followed by Holm-S´ıdak´ 
post hoc test when data were normally distributed, or non-parametric Kruskal-Wallis H Test by ranks followed by 
Dunn’s post hoc test when data did not pass an integrated D’Agostino’s omnibus K2-Pearson normality test. Data 
were analysed using GraphPad Prism® 7. For all tests, *p 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.001 were 
considered to be statistically significant.
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